The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 165 Patients with Tubercular Anterior Uveitis

被引:8
|
作者
Agrawal, Rupesh [1 ,2 ,3 ,4 ]
Betzler, Bjorn [1 ,4 ]
Testi, Ilaria [3 ]
Mahajan, Sarakshi [5 ]
Agarwal, Aniruddha [6 ]
Gunasekeran, Dinesh Visva [2 ,3 ]
Raje, Dhananjay [7 ]
Aggarwal, Kanika [6 ]
Murthy, Somasheila, I [8 ]
Westcott, Mark [3 ]
Chee, Soon-Phaik [1 ,4 ,9 ,10 ]
Mccluskey, Peter [11 ]
Ho, Su Ling [2 ]
Teoh, Stephen [2 ]
Cimino, Luca [12 ]
Biswas, Jyotirmay [13 ]
Narain, Shishir [14 ]
Agarwal, Manisha [15 ]
Mahendradas, Padmamalini [16 ]
Khairallah, Moncef [17 ]
Jones, Nicholas [18 ]
Tugal-Tutkun, Ilknur [19 ]
Babu, Kalpana [20 ]
Basu, Soumayava [21 ]
Carreno, Ester [22 ]
Lee, Richard [3 ]
Al-Dhibi, Hassan [23 ]
Bodaghi, Bahram [24 ]
Invernizzi, Alessandro [25 ]
Goldstein, Debra A. [26 ]
Herbort, Carl P. [27 ,28 ]
Barisani-Asenbauer, Talin [29 ]
Gonzalez-Lopez, Julio J. [30 ]
Androudi, Sofia [31 ]
Bansal, Reema [6 ]
Moharana, Bruttendu [6 ]
Esposti, Simona [3 ]
Tasiopoulou, Anastasia [3 ]
Nadarajah, Sengal [3 ]
Agarwal, Mamta [13 ]
Abraham, Sharanya [13 ]
Vala, Ruchi [16 ]
Singh, Ramandeep [6 ]
Sharma, Aman [32 ]
Sharma, Kusum [33 ]
Zierhut, Manfred [34 ]
Kon, Onn Min [35 ]
Cunningham, Emmett T. [36 ]
Kempen, John H. [37 ,38 ,39 ]
Nguyen, Quan Dong [5 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore
[2] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore
[3] NHS Fdn Trust, Mootfields Eye Hosp, London, England
[4] Singapore Eye Res Inst, Singapore, Singapore
[5] Stanford Univ, Byres Eye Inst, Palo Alto, CA 94304 USA
[6] Postgrad Inst Med Educ & Res PGIMER, Adv Eye Ctr, Chandigarh, India
[7] MDS Bioanalyt, Nagpur, Maharashtra, India
[8] LV Prasad Eye Inst, Tej Kohli Cornea Inst, Kallam Anji Reddy Campus, Hyderabad, India
[9] Singapore Natl Eye Ctr, Singapore, Singapore
[10] Duke NUS Med Sch, Acad Clin Program, Dept Ophthalmol & Visual Sci, Singapore, Singapore
[11] Univ Sydney, Cent Clin Sch, Save Sight Inst, Dept Clin Ophthalmol & Eye Hlth, Sydney, NSW, Australia
[12] Azienda USL IRCCS, Ocular Immunol Unit, Reggio Emilia, Italy
[13] Sankara Nethralaya, Dept Ophthalmol, Chennai, Tamil Nadu, India
[14] Shroff Eye Ctr, Dept Ophthalmol, New Delhi, India
[15] Dr Shroffs Char Eye Hosp Daryaganj, Dept Ophthalmol, New Delhi, India
[16] Narayana Nethralaya, Dept Uveitis & Ocular Immunol, Bangalore, Karnataka, India
[17] Univ Monastir, Fattouma Bourguiba Univ Hosp, Fac Med, Dept Ophthalmol, Singapore, Singapore
[18] Univ Manchester, Dept Ophthalmol, Manchester, Lancs, England
[19] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey
[20] Vittala Int Inst Ophthalmol, Prabha Eye Clin & Res Ctr, Bangalore, Karnataka, India
[21] LV Prasad Eye Inst, Dept Ophthalmol, Bhubaneswar, India
[22] Hosp Univ Fdn Jimenez Diaz, Serv Oftalmol, Madrid, Spain
[23] King Khalid Eye Specialist Hosp, Dept Ophthalmol, Riyadh, Saudi Arabia
[24] Sorbonne Univ, Dept Ophthalmol, DHU SightRestore, Paris, France
[25] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci L Sacco, Eye Clin, Milan, Italy
[26] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA
[27] Ctr Ophthalm Specialised Care, Lausanne, Switzerland
[28] Univ Lausanne, Lausanne, Switzerland
[29] Med Univ Vienna, Ctr Ocular Inflammat & Infect OCUVAC, Laura Bassi Ctr Expertise Ctr Pathophysiol, Vienna, Austria
[30] Ramon y Cajal Univ Hosp, Dept Ophthalmol, Madrid, Spain
[31] Univ Thessaly, Dept Ophthalmol, Volos, Greece
[32] PGIMER, Dept Rheumatol, Chandigarh, India
[33] PGIMER, Dept Microbiol, Chandigarh, India
[34] Univ Tubingen, Ctr Ophthalmol, Dept Ophthalmol, Tubingen, Germany
[35] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Chest & Allergy Clin, London, England
[36] UCSF Sch Med, Francis I Proctor Fdn, San Francisco, CA USA
[37] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA
[38] MyungSung Christian Med Ctr, MCM Eye Unit, Addis Ababa, Ethiopia
[39] MyungSung Med Sch, Addis Ababa, Ethiopia
关键词
Anti-tubercular therapy; tubercular anterior uveitis; ocular tuberculosis; uveitis; collaborative ocular tuberculosis study (COTS); THERAPY; POPULATION; DIAGNOSIS;
D O I
10.1080/09273948.2020.1761400
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose The Collaborative Ocular Tuberculosis Study (COTS) Group sought to address the diagnostic uncertainty through retrospective cohort analysis of treatment regimens and therapeutic outcomes for patients with tubercular Anterior Uveitis (TAU) across international centers. Methods Multicentre retrospective analysis of patients diagnosed with TAU between January 2004 to December 2014 that had a minimum follow-up of 1 year. Results One hundred and sixty-five patients were included. One hundred and seven subjects received antitubercular therapy (ATT) (n = 107/165; 64.9%) with all the patients receiving topical steroid therapy. Treatment failure was noted in 17 patients (n = 17/165; 10.3%), more frequently described in patients that received ATT (n = 13/107, 12.2%), than those that did not receive ATT (n = 4/58, 6.9%). Conclusion In this retrospective study, addition of ATT did not have any statistically significant impact on outcome in patients with TAU.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 33 条
  • [31] Re: Agrawal et al.: Collaborative Ocular Tuberculosis Study consensus guidelines on the management of tubercular uveitisereport 1: Guidelines for initiating antitubercular therapy in tubercular choroiditis (Ophthalmology. 2020 Jan 11;S0161-6420(20)30013-0. https://doi.org/10.1016/j.ophtha.2020.01.008 [Epub ahead of print])
    Venkatesh, Pradeep
    Chawla, Rohan
    Kumar, Vinod
    [J]. OPHTHALMOLOGY, 2020, 127 (11) : E100 - E101
  • [32] PROGRAMMED CELL DEATH LIGAND-1 TESTING AMONG PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER: A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
    Parikh, R. C.
    Klein, A. B.
    Kurosky, S.
    Trantham, L.
    Zhang, Y.
    Levine, C. A.
    Kaye, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S50 - S50
  • [33] Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
    van der Horst-Bruinsma, Irene
    van Bentum, Rianne
    Verbraak, Frank D.
    Rath, Thomas
    Rosenbaum, James T.
    Misterska-Skora, Maria
    Hoepken, Bengt
    Irvin-Sellers, Oscar
    VanLunen, Brenda
    Bauer, Lars
    Rudwaleit, Martin
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71